Upcoming events – pivotal data loom for Novavax and Mallinckrodt
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
Upcoming events – Takeda awaits dengue data and Regenxbio needs more heartening results
Takeda will soon report phase III results with its dengue fever vaccine, while Regenxbio needs an improvement with its cholesterol-lowering gene therapy candidate,…
Oncolytics prepares to tap US investors
The tiny biotech has wasted no time in jumping on the oncolytic virus deal-making bandwagon, but dilution is nevertheless still likely.
Biosimilars the beneficiary of new Medicare step therapy rule
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
Upcoming events – FDA decision for Progenics and Allergy comes out of hiding
Progenics hopes to secure US approval for Azedra, while Allergy Therapeutics awaits phase III data with its birch vaccine.
Hvivo gets second chance in universal flu vaccine chase
One phase II success out of two has convinced Hvivo to push into pivotal trials with its universal flu vaccine candidate, but will potential partners be convinced?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.